All In Biotech

Drug Trial Radar · NCT00478647

Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase

A Multicenter Open-Label Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Patients With Type 1 Gaucher Disease Previously Treated With Imiglucerase

Last checked: Nov 19, 2026Latest source record: Jun 10, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

40

Actual

Start

Jul 25, 2007

Primary completion

Jun 26, 2009

Study completion Jun 26, 2009

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
May 25, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Gaucher disease is a rare lysosomal storage disorder caused by the deficiency of the enzyme glucocerebrosidase (GCB). Due to the deficiency of functional GCB, glucocerebroside accumulates within macrophages leading to cellular engorgement, organomegaly, and organ system dysfunction. The purpose of this study is to evaluate the safety and efficacy of every other week dosing of GA-GCB (velaglucerase alfa) in participants with type 1 Gaucher disease who were previously treated with imiglucerase.

Conditions

  • Gaucher Disease

Interventions

  • GA-GCB (velaglucerase alfa)Biological

    15-60 U/kg, every other week via intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants Who Experienced at Least One Adverse EventTime frame: Week 53

Locations

15 sites in 5 countries. Site status is shown where the registry gives one.

  • Regional Metabolic Center

    Los Angeles, California

  • Children's Hospital Oakland

    Oakland, California

  • Emory University

    Decatur, Georgia

  • Feinberg School of Medicine

    Chicago, Illinois

  • Children's of Minnesota

    Minneapolis, Minnesota

  • Children's Mercy Hospital and Clinic

    Kansas City, Missouri

  • NYU School of Medicine

    New York, New York

  • Cincinatti Children's Hospital

    Cincinnati, Ohio

  • Texas Children's Hospital

    Houston, Texas

  • Medical Genetics/Pediatrics

    Salt Lake City, Utah

  • Children's Hospital of Wisconsin

    Milwaukee, Wisconsin

  • Shaare Zedek Medical Center

    Jerusalem, Israel

  • Children's Memorial Health Institute

    Warsaw, Poland

  • Hospital Universitario Miguel Servet

    Zaragoza, Spain

  • The Royal Free Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.